(Reuters) -Italy's Alfasigma S.p.A agreed on Tuesday to buy drugmaker Intercept Pharmaceuticals for $794 million as it aims to expand its treatment portfolio in liver diseases and digestive system ...

BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the ...

Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage biotechnology company, today announced a strategic partnership ...

Italian pharma company Alfasigma announced Tuesday that it will buy Intercept Pharmaceuticals for $794 million. The acquisition will help boost Alfasigma’s gastroenterology and hepatology pipeline, as ...

Alfasigma S.p.A (Alfasigma), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc., a leading biopharmaceutical company in rare and serious liver diseases, announced ...

Cosmo Pharmaceuticals will receive a €4m upfront payment Alfasigma plus double digit royalties Lumeblue™ was recently approved by EMA for the detection of lesions during colonoscopy Alfasigma will ...

Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. Germany’s ...

After two FDA rejections for non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA), Intercept Pharma has agreed to be taken over by Italian drugmaker Alfasigma in a deal that values the ...

Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to ...

Sept 26 (Reuters) - Italy's Alfasigma S.p.A agreed on Tuesday to buy drugmaker Intercept Pharmaceuticals (ICPT.O), opens new tab for $794 million as it aims to expand its treatment portfolio in liver ...